▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Daewoong pushes for stem cell, diabetes treatment

  • PUBLISHED :June 18, 2018 - 15:51
  • UPDATED :June 18, 2018 - 15:51
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[THE INVESTOR] Daewoong Pharmaceuticals said on June 18 it has completed restructuring its research and development organization to hasten new drug development including diabetes and stem cell therapies.

“This reorganization will be a milestone for Daewoong to become a more flexible and dynamic organization,” company CEO Jeon Seung-ho said.

Under the new scheme, Daewoong’s R&D group now consists of three centers -- new drug center, bio center, new product center -- and two teams -- preclinical study team and research project management team.

The reshuffle is aimed at increasing the success rate of new drug development by assigning each center a specific project. Daewoong plans to spin off the teams as startups if their studies are verified to have competitiveness in terms of technology and investment value when examined by external experts.

The new drug center will focus on the development of six drug candidates including sodium-glucose co-transporter-2 inhibitors for type 2 diabetes, Acid Pump Antagonist for patients with ulcer disease and Prolyl-tRNA Synthetase for anti-fibrosis therapy. The bio center will work on smart stem cell and one stop proof-of-concept, the company said.

By Park Han-na (hnpark@heraldcorp.com)  

EDITOR'S PICKS